ym 872 has been researched along with Arterial Occlusive Diseases in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ichiki, C; Kawasaki-Yatsugi, S; Minematsu, K; Shimizu-Sasamata, M; Takahashi, M; Toya, T; Yamaguchi, T; Yatsugi, S | 1 |
| Håberg, A; Haraldseth, O; Hjelstuen, M; Takahashi, M; Yamaguchi, T | 1 |
| Ni, JW; Shimizu-Sasamata, M; Takahashi, M; Yamaguchi, T; Yatsugi, S | 1 |
3 other study(ies) available for ym 872 and Arterial Occlusive Diseases
| Article | Year |
|---|---|
A novel AMPA receptor antagonist, YM872, reduces infarct size after middle cerebral artery occlusion in rats.
Topics: Animals; Arterial Occlusive Diseases; Blood Gas Analysis; Body Temperature; Brain; Brain Ischemia; Cerebral Arteries; Cerebral Infarction; Disease Models, Animal; Dose-Response Relationship, Drug; Imidazoles; Infusions, Intravenous; Kidney; Male; Neuroprotective Agents; Quinoxalines; Rats; Rats, Sprague-Dawley; Receptors, AMPA; Time Factors | 1998 |
Neuroprotective effect of the novel glutamate AMPA receptor antagonist YM872 assessed with in vivo MR imaging of rat MCA occlusion.
Topics: Animals; Arterial Occlusive Diseases; Cerebral Arterial Diseases; Drug Evaluation, Preclinical; Imidazoles; Linear Models; Magnetic Resonance Imaging; Male; Neuroprotective Agents; Quinoxalines; Rats; Rats, Wistar; Receptors, AMPA | 1998 |
Effects of YM872 on atrophy of substantia nigra reticulata after focal ischemia in rats.
Topics: Animals; Arterial Occlusive Diseases; Atrophy; Body Temperature; Body Weight; Brain Ischemia; Cerebral Infarction; Imidazoles; Male; Neurologic Examination; Neuroprotective Agents; Quinoxalines; Rats; Rats, Inbred F344; Receptors, AMPA; Substantia Nigra | 1998 |